Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion type Assertion NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_head.
- NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion description "[We show that pharmacological inhibition of CD38 results in higher intracellular NAD(+) levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_provenance.
- NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion evidence source_evidence_literature NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_provenance.
- NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion SIO_000772 23172919 NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_provenance.
- NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion wasDerivedFrom befree-20140225 NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_provenance.
- NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_assertion wasGeneratedBy ECO_0000203 NP510621.RAhAoq7CL4De0vn7r7hpsOB-CD1MgcnfOn-l2ssitN2eA130_provenance.